Plus Therapeutics Inc
NASDAQ:PSTV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
US |
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
B
|
BP PLC
XMUN:BPE5
|
UK |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PSTV's stock price target?
Not Available
PSTV does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Plus Therapeutics Inc?
Projected CAGR
107%
Over the last 14 years, the compound annual growth rate for Revenue has been -5%. The projected CAGR for the next 3 years is 107%.